TORONTO, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has dosed the first patient in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.

See the original post:
First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh